Arg20-Pro283 with Human IgG1 Fc & Avi Tag at the C-Terminus
Pan W, Huang W, Zheng J, Meng Z, Pan X. Construction of a prognosis model of head and neck squamous cell carcinoma pyroptosis and an analysis of immuno-phenotyping based on bioinformatics. Transl Cancer Res. 2024 Jan 31;13(1):299-316.
Miao J, Tu Y, Jiang J, Ren R, Wu Q, Liang H, Wang T, Lin B, Wu J, Pan Y, Wang X, Jin H. VSIG4 inhibits RANKL-induced osteoclastogenesis by enhancing Nrf2-dependent antioxidant response against reactive oxygen species production. Int J Biol Macromol. 2024 Mar;260(Pt 2):129357.
VSIG4 (V-set and immunoglobulin domain containing 4), also known as CRIg and Z39IG, is a type I transmembrane protein belonging to the B7 family within the immunoglobulin (Ig) superfamily. It features two Ig-like domains. VSIG4 is highly expressed in various fetal tissues, with the highest levels observed in the lung and placenta of adult tissues.
VSIG4 serves as a negative regulator of T cell activation and is believed to play a role in maintaining peripheral T cell tolerance. Additionally, it has been identified as a potent suppressor of established inflammation. The protein acts as a phagocytic receptor and exerts a strong inhibitory effect on T-cell proliferation and IL-2 production.
2μg (R: reducing condition, N: non-reducing condition).
The purity of Biotinylated VSIG4 Fc&Avi Tag Protein, Human is more than 95% determined by RP-HPLC.
Immobilized human iC3b at 5μg/mL (100μL/well) can bind Biotinylated VSIG4 Fc&Avi Tag Protein, Human(Cat. No. UA011000) with EC50 of 11.82-13.78 ng/mL.